Windtree therapeutics regains compliance with nasdaq listing rules

Warrington, pa., march 24, 2025 (globe newswire) -- windtree therapeutics, inc. (“windtree” or the “company”) (nasdaqcm: wint), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that the company received notice from the nasdaq stock market llc ("nasdaq") that windtree has regained compliance with the minimum bid price requirement under nasdaq listing rule 5550(a)(2) for continued listing on nasdaq. the company will be subject to a mandatory panel monitor until march 20, 2026.
NDAQ Ratings Summary
NDAQ Quant Ranking